Medicare AdvantageCoverageMedium impact
MA06.035a, Rapid Whole Exome Sequencing (rWES) and Rapid Whole Genome Sequencing (rWGS) for Diagnosis of Genetic Disorders
Independence Blue Cross·Pediatrics, Neurology, Oncology +1 more·Medical Policy
Effective date
Jan 1, 2024
We identified it
Jun 19, 2026
Summary
Medicare Advantage has updated its policy MA06.035a regarding coverage and billing for Rapid Whole Exome Sequencing (rWES) and Rapid Whole Genome Sequencing (rWGS) for diagnosing genetic disorders. This policy became effective January 1, 2024, and may affect coverage criteria, prior authorization requirements, or billing procedures for genetic testing services.
Action Required
Immediately: Billing team must review the complete MA06.035a policy document at the provided URL to understand specific changes to rWES and rWGS coverage criteria, prior authorization requirements, and billing procedures for Medicare Advantage plans. Update billing workflows and staff training accordingly based on the detailed policy requirements.